Composition: Each tablet contains Meloxicam 2 mg.
Class/Action: Non-steroidal anti-inflammatory drug (NSAID), oxicam group; acts preferentially on COX-2, inhibiting prostaglandin synthesis and providing anti-inflammatory, analgesic, anti-exudative, and antipyretic effects.
Indications (Dogs & Cats):
Analgesic, anti-inflammatory and antipyretic for acute and chronic musculoskeletal disorders: hip dysplasia, arthritis, osteoarthritis, discospondylitis.
Reduction of pre- and postoperative painafter orthopedic and soft-tissue surgeries (e.g., ovariohysterectomy/spay, castration/neuter, total ear canal ablation).
Pain associated with diagnostic procedures, such as thoracentesis and amniocentesis.
Dosage (Dogs):
Initial: 0.2 mg/kg body weight (1 tablet/10 kg) orally.
Continuation: 0.1 mg/kg (½ tablet/10 kg) every 24 hours for 5–7 days, or as directed by the veterinarian.
Packaging: Box with 10 tablets.
Flavor: Strawberry.
Note: Meloxicam has proven efficacy in degenerative joint disease, helping prevent edema and bone/cartilage deterioration; its anti-arthritic effect is linked to strong COX-2 activity.
Composition: Each tablet contains Meloxicam 2 mg.
Class/Action: Non-steroidal anti-inflammatory drug (NSAID), oxicam group; acts preferentially on COX-2, inhibiting prostaglandin synthesis and providing anti-inflammatory, analgesic, anti-exudative, and antipyretic effects.
Indications (Dogs & Cats):
Analgesic, anti-inflammatory and antipyretic for acute and chronic musculoskeletal disorders: hip dysplasia, arthritis, osteoarthritis, discospondylitis.
Reduction of pre- and postoperative painafter orthopedic and soft-tissue surgeries (e.g., ovariohysterectomy/spay, castration/neuter, total ear canal ablation).
Pain associated with diagnostic procedures, such as thoracentesis and amniocentesis.
Dosage (Dogs):
Initial: 0.2 mg/kg body weight (1 tablet/10 kg) orally.
Continuation: 0.1 mg/kg (½ tablet/10 kg) every 24 hours for 5–7 days, or as directed by the veterinarian.
Packaging: Box with 10 tablets.
Flavor: Strawberry.
Note: Meloxicam has proven efficacy in degenerative joint disease, helping prevent edema and bone/cartilage deterioration; its anti-arthritic effect is linked to strong COX-2 activity.
